Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(11 sites)
United States
Midwest Heart and Vascular, Overland Park, Kansas Johns Hopkins, Baltimore, Maryland St. Luke's Hospital of Kansas City, Kansas City, Missouri Cleveland Clinic, Cleveland, Ohio OHSU (Oregon Health & Science University), Portland, Oregon